BACKGROUND: We examined the distribution and toxicity associated with a single salivary gland administration of a recombinant adenoviral vector, AdCMVH3, encoding human histatin 3. METHODS: Adult rats received different doses of AdCMVH3 (0, 106, 3 x 107, and 109 pfu; 50 microl) via the right submandibular gland and were followed for 15 days. Food consumption, weight gain, clinical appearance, and serum chemistry were monitored, and a necropsy was performed. Vector distribution was examined by polymerase chain reaction, and selected saliva samples were tested for replication-competent adenovirus (RCA). RESULTS: All animals survived to sacrifice (days 2, 8, and 15), and appeared normal clinically. There were no differences in food consumption, weight gain, and serum chemistry. The only consistent necropsy findings were lymphoid infiltrates and necrosis in the target submandibular glands of high-dosage animals. AdCMVH3 detection was virus dose dependent, decreased with time, and at low dose preferentially observed in the targeted gland. No RCA was detected. CONCLUSIONS: Salivary gland administration of 109 pfu AdCMVH3 elicits an initial focal pathologic response and wide tissue distribution. There is no associated systemic toxicity up to 15 days, and lower doses are primarily found in glands.
BACKGROUND: We examined the distribution and toxicity associated with a single salivary gland administration of a recombinant adenoviral vector, AdCMVH3, encoding humanhistatin 3. METHODS: Adult rats received different doses of AdCMVH3 (0, 106, 3 x 107, and 109 pfu; 50 microl) via the right submandibular gland and were followed for 15 days. Food consumption, weight gain, clinical appearance, and serum chemistry were monitored, and a necropsy was performed. Vector distribution was examined by polymerase chain reaction, and selected saliva samples were tested for replication-competent adenovirus (RCA). RESULTS: All animals survived to sacrifice (days 2, 8, and 15), and appeared normal clinically. There were no differences in food consumption, weight gain, and serum chemistry. The only consistent necropsy findings were lymphoid infiltrates and necrosis in the target submandibular glands of high-dosage animals. AdCMVH3 detection was virus dose dependent, decreased with time, and at low dose preferentially observed in the targeted gland. No RCA was detected. CONCLUSIONS: Salivary gland administration of 109 pfu AdCMVH3 elicits an initial focal pathologic response and wide tissue distribution. There is no associated systemic toxicity up to 15 days, and lower doses are primarily found in glands.
Authors: Changyu Zheng; Ana P Cotrim; Anne Rowzee; William Swaim; Anastasia Sowers; James B Mitchell; Bruce J Baum Journal: Clin Cancer Res Date: 2011-03-02 Impact factor: 12.531
Authors: Eduardo M Rocha; Giovanni Di Pasquale; Paola Perez Riveros; Kathrina Quinn; Beverly Handelman; John A Chiorini Journal: Invest Ophthalmol Vis Sci Date: 2011-12-20 Impact factor: 4.799
Authors: Antonis Voutetakis; Marc R Kok; Changyu Zheng; Ioannis Bossis; Jianghua Wang; Ana P Cotrim; Natanya Marracino; Corinne M Goldsmith; John A Chiorini; Y Peng Loh; Lynnette K Nieman; Bruce J Baum Journal: Proc Natl Acad Sci U S A Date: 2004-02-20 Impact factor: 11.205
Authors: Cuong Q Nguyen; Hongen Yin; Byung Ha Lee; Wendy C Carcamo; John A Chiorini; Ammon B Peck Journal: Arthritis Res Ther Date: 2010-12-23 Impact factor: 5.156